Advanced search
Publication Cover
Expert Opinion on Biological Therapy Volume 9, 2009 - Issue 7
Submit an article Journal homepage
199
Views
15
CrossRef citations to date
0
Altmetric
Reviews

DNA vaccine therapy for chronic hepatitis C virus (HCV) infection: immune control of a moving target

Matti Sällberg Karolinska Institutet at Karolinska University Hospital Huddinge, Division of Clinical Microbiology, F68, Department of Laboratory Medicine, S-141 86 Stockholm, Sweden +46 8 52483803; +46 8 58587933; [email protected]
,
Lars Frelin Karolinska Institutet at Karolinska University Hospital Huddinge, Division of Clinical Microbiology, F68, Department of Laboratory Medicine, S-141 86 Stockholm, Sweden +46 8 52483803; +46 8 58587933; [email protected]
&
Ola Weiland Karolinska Institutet at Karolinska University Hospital Huddinge, Division of Infectious Diseases, Department of Medicine, S-141 86 Stockholm, Sweden
Pages 805-815 | Published online: 15 Jun 2009

Bibliography

  • Wolff JA, Malone RW, Williams P, et al. Direct gene transfer into mouse muscle in vivo. Science 1990;247(4949 Pt 1):1465-8
  • Nabel EG, Plautz G, Nabel GJ. Site-specific gene expression in vivo by direct gene transfer into the arterial wall. Science 1990;249(4974):1285-8
  • Tang DC, Devit M, Johnston SA. Genetic immunization is a simple method for eliciting an immune response. Nature 1992;356(6365):152-4
  • Wang B, Ugen KE, Srikantan V, et al. Gene inoculation generates immune responses against human immunodeficiency virus type 1. Proc Natl Acad Sci USA 1993;90(9):4156-60
  • Ulmer JB, Donnelly JJ, Parker SE, et al. Heterologous protection against influenza by injection of DNA encoding a viral protein. Science 1993;259(5102):1745-9
  • Donnelly JJ, Friedman A, Martinez D, et al. Preclinical efficacy of a prototype DNA vaccine: enhanced protection against antigenic drift in influenza virus. Nat Med 1995;1(6):583-7
  • Huygen K, Content J, Denis O, et al. Immunogenicity and protective efficacy of a tuberculosis DNA vaccine. Nat Med 1996;2(8):893-8
  • Wang B, Boyer J, Srikantan V, et al. DNA inoculation induces neutralizing immune responses against human immunodeficiency virus type 1 in mice and nonhuman primates. DNA Cell Biol 1993;12(9):799-805
  • Davis HL, Whalen RG, Demeneix BA. Direct gene transfer into skeletal muscle in vivo: factors affecting efficiency of transfer and stability of expression. Hum Gene Ther 1993;4(2):151-9
  • Davis HL, Michel ML, Whalen RG. DNA-based immunization induces continuous secretion of hepatitis B surface antigen and high levels of circulating antibody. Hum Mol Genet 1993;2(11):1847-51
  • MacGregor RR, Boyer JD, Ugen KE, et al. First human trial of a DNA-based vaccine for treatment of human immunodeficiency virus type 1 infection: safety and host response. J Infect Dis 1998;178(1):92-100
  • Kutzler MA, Weiner DB. DNA vaccines: ready for prime time? Nat Rev Genet 2008;9(10):776-88
  • Boyer JD, Robinson TM, Kutzler MA, et al. Protection against simian/human immunodeficiency virus (SHIV) 89.6P in macaques after coimmunization with SHIV antigen and IL-15 plasmid. Proc Natl Acad Sci USA 2007;104(47):18648-53
  • Chong SY, Egan MA, Kutzler MA, et al. Comparative ability of plasmid IL-12 and IL-15 to enhance cellular and humoral immune responses elicited by a SIVgag plasmid DNA vaccine and alter disease progression following SHIV89.6P challenge in rhesus macaques. Vaccine 2007;25(26):4967-82
  • Boyer JD, Robinson TM, Kutzler MA, et al. SIV DNA vaccine co-administered with IL-12 expression plasmid enhances CD8 SIV cellular immune responses in cynomolgus macaques. J Med Primatol 2005;34(5-6):262-70
  • Kutzler MA, Robinson TM, Chattergoon MA, et al. Coimmunization with an optimized IL-15 plasmid results in enhanced function and longevity of CD8 T cells that are partially independent of CD4 T cell help. J Immunol 2005;175(1):112-23
  • Davis BS, Chang GJ, Cropp B, et al. West Nile virus recombinant DNA vaccine protects mouse and horse from virus challenge and expresses in vitro a noninfectious recombinant antigen that can be used in enzyme-linked immunosorbent assays. J Virol 2001;75(9):4040-7
  • Anderson ED, Mourich DV, Fahrenkrug SC, et al. Genetic immunization of rainbow trout (Oncorhynchus mykiss) against infectious hematopoietic necrosis virus. Mol Mar Biol Biotechnol 1996;5(2):114-22
  • Anderson ED, Mourich DV, Leong JA. Gene expression in rainbow trout (Oncorhynchus mykiss) following intramuscular injection of DNA. Mol Mar Biol Biotechnol 1996;5(2):105-13
  • Lorenzen N, Lorenzen E, Einer-Jensen K, et al. Genetic vaccination of rainbow trout against viral haemorrhagic septicaemia virus: small amounts of plasmid DNA protect against a heterologous serotype. Virus Res 1999;63(1-2):19-25
  • Klein TM, Wolf ED, Wu R, Sanford CJ. High-velocity microprojectiles for delivering nucleic acids into living cells. Nature 1987;327:70-3
  • Johnston SA, Anziano PQ, Shark K, et al. Mitochondrial transformation in yeast by bombardment with microprojectiles. Science 1988;240(4858):1538-41
  • Zelenin AV, Titomirov AV, Kolesnikov VA. Genetic transformation of mouse cultured cells with the help of high-velocity mechanical DNA injection. FEBS Lett 1989;244(1):65-7
  • Yang NS, Burkholder J, Roberts B, et al. In vivo and in vitro gene transfer to mammalian somatic cells by particle bombardment. Proc Natl Acad Sci USA 1990;87(24):9568-72
  • Roy MJ, Wu MS, Barr LJ, et al. Induction of antigen-specific CD8 + T cells, T helper cells, and protective levels of antibody in humans by particle-mediated administration of a hepatitis B virus DNA vaccine. Vaccine 2000;19(7-8):764-78
  • Neumann E, Rosenheck K. Permeability changes induced by electric impulses in vesicular membranes. J Membr Biol 1972;10(3):279-90
  • Neumann E, Schaefer-Ridder M, Wang Y, Hofschneider PH. Gene transfer into mouse lyoma cells by electroporation in high electric fields. EMBO J 1982;1(7):841-5
  • Belehradek M, Domenge C, Luboinski B, et al. Electrochemotherapy, a new antitumor treatment. First clinical Phase I-II trial. Cancer 1993;72(12):3694-700
  • Heller R, Jaroszeski MJ, Glass LF, et al. Phase I/II trial for the treatment of cutaneous and subcutaneous tumors using electrochemotherapy. Cancer 1996;77(5):964-71
  • Heller R, Jaroszeski M, Atkin A, et al. In vivo gene electroinjection and expression in rat liver. FEBS Lett 1996;389(3):225-8
  • Aihara H, Miyazaki J. Gene transfer into muscle by electroporation in vivo. Nat Biotechnol 1998;16(9):867-70
  • Mathiesen I. Electropermeabilization of skeletal muscle enhances gene transfer in vivo. Gene Ther 1999;6(4):508-14
  • Rols MP, Delteil C, Golzio M, et al. In vivo electrically mediated protein and gene transfer in murine melanoma. Nat Biotechnol 1998;16(2):168-71
  • Rice J, Ottensmeier CH, Stevenson FK. DNA vaccines: precision tools for activating effective immunity against cancer. Nat Rev Cancer 2008;8(2):108-20
  • Ploss A, Evans MJ, Gaysinskaya VA, et al. Human occludin is a hepatitis C virus entry factor required for infection of mouse cells. Nature 2009;457(7231):882-6
  • Evans MJ, von Hahn T, Tscherne DM, et al. Claudin-1 is a hepatitis C virus co-receptor required for a late step in entry. Nature 2007;446(7137):801-5
  • Moradpour D, Penin F, Rice CM. Replication of hepatitis C virus. Nat Rev Microbiol 2007;5(6):453-63
  • Bartenschlager R, Ahlborn-Laake L, Mous J, Jacobsen H. Nonstructural protein 3 of the hepatitis C virus encodes a serine-type proteinase required for cleavage at the NS3/4 and NS4/5 junctions. J Virol 1993;67(7):3835-44
  • Bartenschlager R, Ahlborn-Laake L, Mous J, Jacobsen H. Kinetic and structural analyses of hepatitis C virus polyprotein processing. J Virol 1994;68(8):5045-55
  • Bartenschlager R, Ahlborn-Laake L, Yasargil K, et al. Substrate determinants for cleavage in cis and in trans by the hepatitis C virus NS3 proteinase. J Virol 1995;69(1):198-205
  • Miyanari Y, Atsuzawa K, Usuda N, et al. The lipid droplet is an important organelle for hepatitis C virus production. Nat Cell Biol 2007;9(9):1089-97
  • Lohmann V, Korner F, Koch J, et al. Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line. Science 1999;285(5424):110-3
  • Wakita T, Pietschmann T, Kato T, et al. Production of infectious hepatitis C virus in tissue culture from a cloned viral genome. Nat Med 2005;11(7):791-6
  • Shepard CW, Finelli L, Alter MJ. Global epidemiology of hepatitis C virus infection. Lancet Infect Dis 2005;5(9):558-67
  • Chen M, Sallberg M, Sonnerborg A, et al. Limited humoral immunity in hepatitis C virus infection. Gastroenterology 1999;116(1):135-43
  • Farci P, Alter HJ, Govindarajan S, et al. Lack of protective immunity against reinfection with hepatitis C virus. Science 1992;258(5079):135-40
  • Zhang ZX, Chen M, Sonnerborg A, et al. Distinguishing acute from symptomatic chronic hepatitis C virus (HCV) infection by site-directed serology of the HCV structural proteins. J Infect Dis 1995;171(5):1356-9
  • Spada E, Mele A, Berton A, et al. Multispecific T cell response and negative HCV RNA tests during acute HCV infection are early prognostic factors of spontaneous clearance. Gut 2004;53(11):1673-81
  • Rehermann B, Nascimbeni M. Immunology of hepatitis B virus and hepatitis C virus infection. Nat Rev Immunol 2005;5(3):215-29
  • Nascimbeni M, Mizukoshi E, Bosmann M, et al. Kinetics of CD4 + and CD8 + memory T-cell responses during hepatitis C virus rechallenge of previously recovered chimpanzees. J Virol 2003;77(8):4781-93
  • Thimme R, Bukh J, Spangenberg HC, et al. Viral and immunological determinants of hepatitis C virus clearance, persistence, and disease. Proc Natl Acad Sci USA 2002;99(24):15661-8
  • Disson O, Haouzi D, Desagher S, et al. Impaired clearance of virus-infected hepatocytes in transgenic mice expressing the hepatitis C virus polyprotein. Gastroenterology 2004;126:859-72
  • Foy E, Li K, Wang C, et al. Regulation of interferon regulatory factor-3 by the hepatitis C virus serine protease. Science 2003;300(5622):1145-8
  • Frelin L, Brenndorfer ED, Ahlen G, et al. The hepatitis C virus and immune evasion: non-structural 3/4A transgenic mice are resistant to lethal tumour necrosis factor α mediated liver disease. Gut 2006;55(10):1475-83
  • Gale M Jr, Foy EM. Evasion of intracellular host defence by hepatitis C virus. Nature 2005;436(7053):939-45
  • Li K, Foy E, Ferreon JC, et al. Immune evasion by hepatitis C virus NS3/4A protease-mediated cleavage of the Toll-like receptor 3 adaptor protein TRIF. Proc Natl Acad Sci USA 2005;102(8):2992-7
  • Meylan E, Curran J, Hofmann K, et al. Cardif is an adaptor protein in the RIG-I antiviral pathway and is targeted by hepatitis C virus. Nature 2005;437(7062):1167-72
  • Erickson AL, Kimura Y, Igarashi S, et al. The outcome of hepatitis C virus infection is predicted by escape mutations in epitopes targeted by cytotoxic T lymphocytes. Immunity 2001;15(6):883-95
  • Weiner A, Erickson AL, Kansopon J, et al. Persistent hepatitis C virus infection in a chimpanzee is associated with emergence of a cytotoxic T lymphocyte escape variant. Proc Natl Acad Sci USA 1995;92(7):2755-9
  • Grakoui A, Shoukry NH, Woollard DJ, et al. HCV persistence and immune evasion in the absence of memory T cell help. Science 2003;302(5645):659-62
  • Timm J, Lauer GM, Kavanagh DG, et al. CD8 epitope escape and reversion in acute HCV infection. J Exp Med 2004;200(12):1593-604
  • Diepolder HM, Zachoval R, Hoffmann RM, et al. Possible mechanism involving T-lymphocyte response to non-structural protein 3 in viral clearance in acute hepatitis C virus infection. Lancet 1995;346(8981):1006-7
  • Missale G, Cariani E, Lamonaca V, et al. Effects of interferon treatment on the antiviral T-cell response in hepatitis C virus genotype 1b- and genotype 2c-infected patients. Hepatology 1997;26(3):792-7
  • Cox AL, Mosbruger T, Lauer GM, et al. Comprehensive analyses of CD8 + T cell responses during longitudinal study of acute human hepatitis C. Hepatology 2005;42(1):104-12
  • Cox AL, Mosbruger T, Mao Q, et al. Cellular immune selection with hepatitis C virus persistence in humans. J Exp Med 2005;201(11):1741-52
  • Dazert E, Neumann-Haefelin C, Bressanelli S, et al. Loss of viral fitness and cross recognition by CD8 + T cells limit HCV escape from a protective HLA-B27-restricted human immune response. J Clin Invest 2009;119(2):376-86
  • Soderholm J, Ahlen G, Kaul A, et al. Relation between viral fitness and immune escape within the hepatitis C virus protease. Gut 2006;55:266-74
  • Lang L. HCV findings presented at EASL: long-term follow-up and the criteria of a cure. Gastroenterology 2007;132(7):2282-3
  • Kamar N, Toupance O, Buchler M, et al. Evidence that clearance of hepatitis C virus RNA after α-interferon therapy in dialysis patients is sustained after renal transplantation. J Am Soc Nephrol 2003;14(8):2092-8
  • Pawlotsky JM. Therapy of hepatitis C: from empiricism to eradication. Hepatology 2006;43(2 Suppl 1):S207-20
  • Quiroga JA, Llorente S, Castillo I, et al. Cellular immune responses associated with occult hepatitis C virus infection of the liver. J Virol 2006;80(22):10972-9
  • Quiroga JA, Carreno V. HCV-indeterminate blood donors or occult HCV infection? Lancet 2005;365(9470):1540-1
  • Welker MW, Zeuzem S. Occult hepatitis C: how convincing are the current data? Hepatology 2009;49(2):665-75
  • Manns MP, Foster GR, Rockstroh JK, et al. The way forward in HCV treatment–finding the right path. Nat Rev Drug Discov 2007;6(12):991-1000
  • Reichard O, Andersson J, Schvarcz R, Weiland O. Ribavirin treatment for chronic hepatitis C. Lancet 1991;337(8749):1058-61
  • Di Bisceglie AM, Conjeevaram HS, Fried MW, et al. Ribavirin as therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 1995;123(12):897-903
  • Forestier N, Reesink HW, Weegink CJ, et al. Antiviral activity of telaprevir (VX-950) and peginterferon alfa-2a in patients with hepatitis C. Hepatology 2007;46(3):640-8
  • Lamarre D, Anderson PC, Bailey M, et al. An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus. Nature 2003;426(6963):186-9
  • Sarrazin C, Kieffer TL, Bartels D, et al. Dynamic hepatitis C virus genotypic and phenotypic changes in patients treated with the protease inhibitor telaprevir. Gastroenterology 2007;132(5):1767-77
  • Leroux-Roels G, Batens AH, Desombere I, et al. Immunogenicity and tolerability of intradermal administration of an HCV E1-based vaccine candidate in healthy volunteers and patients with resolved or ongoing chronic HCV infection. Hum Vaccin 2005;1(2):61-5
  • Nevens F, Roskams T, Van Vlierberghe H, et al. A pilot study of therapeutic vaccination with envelope protein E1 in 35 patients with chronic hepatitis C. Hepatology 2003;38(5):1289-96
  • Klade CS, Wedemeyer H, Berg T, et al. Therapeutic vaccination of chronic hepatitis C nonresponder patients with the peptide vaccine IC41. Gastroenterology 2008;134(5):1385-95
  • Schlaphoff V, Klade CS, Jilma B, et al. Functional and phenotypic characterization of peptide-vaccine-induced HCV-specific CD8 + T cells in healthy individuals and chronic hepatitis C patients. Vaccine 2007;25(37-38):6793-806
  • Firbas C, Jilma B, Tauber E, et al. Immunogenicity and safety of a novel therapeutic hepatitis C virus (HCV) peptide vaccine: a randomized, placebo controlled trial for dose optimization in 128 healthy subjects. Vaccine 2006;24(20):4343-53
  • Gordon EJ, Bhat R, Liu Q, et al. Immune responses to hepatitis C virus structural and nonstructural proteins induced by plasmid DNA immunizations. J Infect Dis 2000;181(1):42-50
  • Choo QL, Richman KH, Han JH, et al. Genetic organization and diversity of the hepatitis C virus. Proc Natl Acad Sci USA 1991;88(6):2451-5
  • Nakano I, Maertens G, Major ME, et al. Immunization with plasmid DNA encoding hepatitis C virus envelope E2 antigenic domains induces antibodies whose immune reactivity is linked to the injection mode. J Virol 1997;71(9):7101-9
  • Forns X, Payette PJ, Ma X, et al. Vaccination of chimpanzees with plasmid DNA encoding the hepatitis C virus (HCV) envelope E2 protein modified the infection after challenge with homologous monoclonal HCV. Hepatology 2000;32(3):618-25
  • Arichi T, Saito T, Major ME, et al. Prophylactic DNA vaccine for hepatitis C virus (HCV) infection: HCV-specific cytotoxic T lymphocyte induction and protection from HCV-recombinant vaccinia infection in an HLA-A2.1 transgenic mouse model. Proc Natl Acad Sci USA 2000;97(1):297-302
  • Inchauspe G, Major ME, Nakano I, et al. DNA vaccination for the induction of immune responses against hepatitis C virus proteins. Vaccine 1997;15(8):853-6
  • Inchauspe G, Vitvitski L, Major ME, et al. Plasmid DNA expressing a secreted or a nonsecreted form of hepatitis C virus nucleocapsid: comparative studies of antibody and T-helper responses following genetic immunization. DNA Cell Biol 1997;16(2):185-95
  • Major ME, Vitvitski L, Mink MA, et al. DNA-based immunization with chimeric vectors for the induction of immune responses against the hepatitis C virus nucleocapsid. J Virol 1995;69(9):5798-805
  • Alvarez-Lajonchere L, Shoukry NH, Gra B, et al. Immunogenicity of CIGB-230, a therapeutic DNA vaccine preparation, in HCV-chronically infected individuals in a Phase I clinical trial. J Viral Hepat 2009;16(3):156-67
  • Lerat H, Honda M, Beard MR, et al. Steatosis and liver cancer in transgenic mice expressing the structural and nonstructural proteins of hepatitis C virus. Gastroenterology 2002;122(2):352-65
  • Moriya K, Fujie H, Shintani Y, et al. The core protein of hepatitis C virus induces hepatocellular carcinoma in transgenic mice. Nat Med 1998;4(9):1065-7
  • Levrero M. Viral hepatitis and liver cancer: the case of hepatitis C. Oncogene 2006;25(27):3834-47
  • Lagging LM, Meyer K, Hoft D, et al. Immune responses to plasmid DNA encoding the hepatitis C virus core protein. J Virol 1995;69(9):5859-63
  • Geissler M, Gesien A, Tokushige K, Wands JR. Enhancement of cellular and humoral immune responses to hepatitis C virus core protein using DNA-based vaccines augmented with cytokine-expressing plasmids. J Immunol 1997;158(3):1231-7
  • Liao G, Wang Y, Chang J, et al. Hepatitis B virus precore protein augments genetic immunizations of the truncated hepatitis C virus core in BALB/c mice. Hepatology 2008;47(1):25-34
  • Brenndörfer ED, Karthe J, Frelin L, et al. The non-structural 3/4A protease of HCV activates EGF-induced signal-transduction by cleavage of the T-cell protein tyrosine phosphatase. Hepatology 2009; published online 23 Jan 2009
  • Encke J, zu Putlitz J, Geissler M, Wands JR. Genetic immunization generates cellular and humoral immune responses against the nonstructural proteins of the hepatitis C virus in a murine model. J Immunol 1998;161(9):4917-23
  • Frelin L, Ahlen G, Alheim M, et al. Codon optimization and mRNA amplification effectively enhances the immunogenicity of the hepatitis C virus nonstructural 3/4A gene. Gene Ther 2004;11(6):522-33
  • Frelin L, Alheim M, Chen A, et al. Low dose and gene gun immunization with a hepatitis C virus nonstructural (NS) 3 DNA-based vaccine containing NS4A inhibit NS3/4A-expressing tumors in vivo. Gene Ther 2003;10(8):686-99
  • Ahlen G, Nystrom J, Pult I, et al. In vivo clearance of hepatitis C virus nonstructural 3/4A-expressing hepatocytes by DNA vaccine-primed cytotoxic T lymphocytes. J Infect Dis 2005;192(12):2112-6
  • Ahlen G, Weiland M, Derk E, et al. Cleavage of the IPS-1/Cardif/MAVS/VISA does not inhibit T cell-mediated elimination of hepatitis C virus non-structural 3/4A-expressing hepatocytes. Gut 2009;58(4):560-9
  • Rollier CS, Paranhos-Baccala G, Verschoor EJ, et al. Vaccine-induced early control of hepatitis C virus infection in chimpanzees fails to impact on hepatic PD-1 and chronicity. Hepatology 2007;45(3):602-13
  • Capone S, Zampaglione I, Vitelli A, et al. Modulation of the immune response induced by gene electrotransfer of a hepatitis C virus DNA vaccine in nonhuman primates. J Immunol 2006;177(10):7462-71
  • Folgori A, Capone S, Ruggeri L, et al. A T-cell HCV vaccine eliciting effective immunity against heterologous virus challenge in chimpanzees. Nat Med 2006;12(2):190-7
  • Pala P, Bodmer HC, Pemberton RM, et al. Competition between unrelated peptides recognized by H-2-Kd restricted T cells. J Immunol 1988;141(7):2289-94
  • Palmowski MJ, Choi EM, Hermans IF, et al. Competition between CTL narrows the immune response induced by prime-boost vaccination protocols. J Immunol 2002;168(9):4391-8
  • Ahlen G, Soderholm J, Tjelle TE, et al. In vivo electroporation enhances the immunogenicity of hepatitis C virus nonstructural3/4A DNA by increased local DNA uptake, protein expression, inflammation, and infiltration of CD3 + cells. J Immunol 2007;179(7):4741-53
  • Hinkula J, Svanholm C, Schwartz S, et al. Recognition of prominent viral epitopes induced by immunization with human immunodeficiency virus type 1 regulatory genes. J Virol 1997;71(7):5528-39
  • Brinster C, Chen M, Boucreux D, et al. Hepatitis C virus non-structural protein 3-specific cellular immune responses following single or combined immunization with DNA or recombinant Semliki Forest virus particles. J Gen Virol 2002;83(Pt 2):369-81
  • Cheng G, Zhong J, Chisari FV. Inhibition of dsRNA-induced signaling in hepatitis C virus-infected cells by NS3 protease dependent and -independent mechanisms. Proc Natl Acad Sci USA 2006;103(22):8499-504
  • Lazdina U, Hultgren C, Frelin L, et al. Humoral and CD4 + T helper (Th) cell responses to the hepatitis C virus non-structural 3 (NS3) protein: NS3 primes Th1-like responses more effectively as a DNA-based immunogen than as a recombinant protein. J Gen Virol 2001;82(Pt 6):1299-308
  • Sallberg M, Diepolder H, Jung MC, et al. Antiviral effects of therapeutic vaccination with naked DNA delivered by in vivo electroporation in patients with chronic hepatitis C. Hepatology 2008;48(Suppl):1022A-3A

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.